Can Fite Biopharma News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.11.19	Can-Fite Reports Third Quarter 2019 Financial Results & Provides Clinical Update (Businesswire)
21.11.19	Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on November 25, 2019 (Businesswire)
19.11.19	Can-Fite Granted Patents for its Sexual Dysfunction Drug (Businesswire)
11.11.19	Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market (Businesswire)
04.11.19	Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients (Businesswire)
31.10.19	U.S. FDA Agreed with Can-Fite’s Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer (Businesswire)
17.10.19	Can-Fite and Gebro Pharma holding European Conference on Development & Commercialization of Phase III Drug Candidate Piclidenoson in the Treatment of Rheumatoid Arthritis (Businesswire)
16.10.19	Can-Fite BioPharma Interview to Air on Bloomberg International on the RedChip Money Report (Businesswire)
15.10.19	Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson™ (Businesswire)
10.10.19	Can Fite Announces Publication of Namodenoson™ NASH Mechanism of Action in International Journal of Molecular Medicine (Businesswire)
23.09.19	Can-Fite Presents New Data on the Treatment of Advanced Liver Cancer with Namodenoson at the ILCA Conference (Businesswire)
10.09.19	Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays (Businesswire)
29.08.19	Can-Fite Reports Second Quarter 2019 Financial Results & Provides Clinical Update (Businesswire)
06.08.19	Can-Fite to Treat Advanced Liver Cancer Patients with Namodenoson Under Compassionate Use Setting in Israel (Businesswire)
04.06.19	Can-Fite Participating in One-on-One Partnering Meetings at the BIO International Convention on June 3-6, 2019 (Businesswire)
03.06.19	Findings from Can-Fite’s Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session (Businesswire)
29.05.19	Can-Fite Reports First Quarter 2019 Financial Results & Provides Clinical Update (Businesswire)
23.05.19	The Anti-NASH Effect of Namodenoson will be Presented at the International Conference on Fatty Liver in Berlin (Businesswire)
20.05.19	Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA) (Businesswire)
06.05.19	Can-Fite Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson (Businesswire)
01.05.19	Can-Fite Announces ADS Ratio Change (Businesswire)
15.04.19	Can-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South Korea (Businesswire)
10.04.19	Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting (Businesswire)
02.04.19	Can-Fite BioPharma Announces $3.2 Million Registered Direct Offering (Businesswire)
29.03.19	Can-Fite Files Annual Report for the Year Ended December 31, 2018 (Businesswire)
28.03.19	Can-Fite Reports 2018 Financial Results & Provides Clinical Update (Businesswire)
26.03.19	Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson (Businesswire)
27.02.19	Can-Fite to Participate in Bio Asia International Conference on March 5-6, 2019 in Tokyo (Businesswire)
25.02.19	Can-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication (Businesswire)
04.02.19	Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug (Businesswire)
30.01.19	Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal (Businesswire)
24.01.19	Can-Fite BioPharma CEO Letter to Shareholders (Businesswire)
18.01.19	Can-Fite BioPharma Announces Registered Direct Offering (Businesswire)
08.01.19	Can-Fite: Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent (Businesswire)
03.01.19	Can-Fite to Participate in the Biotech Showcase™ 2019 and BIO One-on-One Partnering™@ JPM 2019 During the JP Morgan Healthcare Conference (Businesswire)
20.11.18	Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert (Businesswire)
31.10.18	Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19 (Businesswire)
25.10.18	Can-Fite to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor Conference (Businesswire)
18.10.18	Can-Fite CEO to present as Expert Speaker on Namodenoson at NASH Summit Europe 2018 (Businesswire)
12.09.18	Can-Fite to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases (AASLD) (Businesswire)
04.09.18	Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected by End of Year (Businesswire)
31.08.18	Can-Fite Reports Second Quarter 2018 Financial Results and Provides Clinical Update (Businesswire)
29.08.18	Can-Fite BioPharma Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018 (Businesswire)
21.08.18	Can-Fite Announces Enrollment of First Patient in its Comfort™ Phase III Trial of Piclidenoson in Psoriasis (Businesswire)
07.08.18	Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China (Businesswire)
06.08.18	Can-Fite Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical (Businesswire)
29.05.18	Ameritech Financial Recommends That Borrowers Get to Know Their Loans (PR Newswire)
10.05.18	Ninety-One Percent Of Pet Owners Are Not Prepared For The Next Disaster, New Banfield Pet Hospital® Survey Shows (PR Newswire)
23.03.18	Can-Fite Reports 2017 Financial Results & Provides Clinical Update (Businesswire)
09.03.18	Can-Fite BioPharma Announces $5 Million Registered Direct Offering (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Holcim	91.22	1.56 %	K V
Sonova Hldg	319.70	1.56 %	K V
Lonza Grp	591.00	1.34 %	K V
Sika	231.50	1.27 %	K V
CieFinRichemont	171.70	0.94 %	K V
Swiss Re	138.05	-0.40 %	K V
Zurich Insur Gr	537.20	-0.52 %	K V
Kuehne+Nagel Int	204.60	-0.97 %	K V
Part Grp Hldg	1’389.50	-1.03 %	K V
Givaudan	3’818.00	-3.12 %	K V

Nachrichten zu Can Fite Biopharma Ltd (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten